Marco Maruzzo
@therealmarcodoc
Followers
45
Following
152
Statuses
77
Oncologo GU, ricercatore, libero pensatore | @iov_irccs | @UniPadova | @unipr | “Nella vita bisognerebbe essere sempre un po' improbabili”
Joined December 2023
RT @jordanciuro: Updates of STOPCAP? #GU25 STOPCAP shares 7 trials identifying who benefits from ARPi in mHSPC… ✅Benefit of intensificati…
0
7
0
RT @DrYukselUrun: TALAPRO-2 Final OS Data: TALA+ENZA in 1L mCRPC @neerajaiims 👏👏👏 🧬TALA+ENZA significantly improves OS vs ENZA alone in al…
0
17
0
RT @DrChoueiri: My dear friend @neerajaiims presenting #TALAPRO2 final OS analysis: TALA + ENZA significantly improved OS vs PBO + ENZA in…
0
18
0
RT @giannatempopatr: Wonderful day at the #SIURO2024 congress in Bologna! A great society that brings together Italian oncologists @thereal…
0
3
0
RT @tompowles1: Perioperative durvalumab + neoadjuvant chemo & cystectomy in operable bladder cancer significantly delays (HR 0.68) event f…
0
122
0
RT @NEJM: Neoadjuvant chemotherapy plus durvalumab, followed by adjuvant durvalumab after cystectomy, led to event-free survival superior t…
0
104
0
RT @tompowles1: Tivozanib +/- nivolumab in IO pretreated M1 renal cancer showed retreatment with IO makes absolutely no difference. This is…
0
56
0
RT @DrIacovelli: @ciccarese_c rocked the stage presenting preliminary data of TACITO trial investigating #FMT on #mRCC. Primary endpoint 1-…
0
12
0
RT @tompowles1: Nectin-4 is the target for Enfortumab Vedotin and is widely expressed in UC (median 275/300) . EV302 is 1st randomised tria…
0
56
0
RT @tompowles1: The 1st disitimab Vedotin (HER-2 MMAE ADC) & pembro showing 1st line response rates of 75% in HER 1-3+ UC. Toxicity profile…
0
53
0
RT @drenriquegrande: 🚨 Exciting Update! 🚨 Our new EVITA (EV Ineligible criTeriA) criteria for identifying patients ineligible for the EV/Pe…
0
62
0
RT @AIOMtweet: Le interviste del Congresso Nazionale #AIOMGiovani 2024 sono disponibili su AIOM Tv: @rossana_berar…
0
5
0
RT @UroDocAsh: The IBCG Quick Guide to Non-Muscle Invasive Bladder Cancer (NMIBC) Bladder Cancer Quick Reference Sheet summarizes essentia…
0
159
0
RT @DrChoueiri: Relevant presentation by Eva Katharina Masel on integrating #palliative care into the management of GU cancers! #ASCO24
@M…
0
13
0
RT @DrYukselUrun: Enfortumab Vedotin consistently improves PFS and OS compared to chemotherapy, regardless of dose modifications, ⭕️ Dose…
0
19
0
RT @tompowles1: 40% response rate for chemo +pembro in advanced penile cancer #ASCO24 HPV16-positive (cORR 55.6%) and TMB-high (cORR 75%) p…
0
42
0
RT @DrChoueiri: Masterful presentation by #FernandoMaluf presenting results of the #HERCULES LACOG 2018 trial #ASCO24 ⚪️ First trial to d…
0
38
0
RT @AndreaNecchi: Interesting data from Maluf @LACOG_group #HERCULES trial in penile cancer. 40%ORR makes a compelling comparison with esta…
0
15
0
RT @tompowles1: The javelin 100 maintenance avelumab trial include ~100 patients who did not have pure UC (such as squamous differentiation…
0
26
0
RT @tompowles1: Biomarker data from KN426 (axi/pembro vs sunitinib) in 1st line RCC. Within arm analysis show T cell signature ⬆️ responses…
0
22
0